Vaxart Inc (VXRT) Q1 2026 Earnings Call Transcript

Why It Matters

The results highlight Novavax's shift from product sales to a royalty‑driven, partnership‑centric model that can generate billions in future cash flow while maintaining a strong balance sheet.

Key Takeaways

• Q1 revenue $140M, down 79% YoY
• Supply sales up 139% to $33M
• Licensing royalties $97M, up 116%
• Cash $818M, runway through 2028
• New Matrix-M MTAs with top pharma expand pipeline

Pulse Analysis

Novavax’s first‑quarter earnings underscore a strategic pivot from traditional vaccine sales to a diversified, royalty‑based revenue engine. While total revenue fell sharply due to the absence of a one‑time non‑cash Nuvaxovid sale, the company offset the decline with robust supply sales and a surge in licensing royalties. Cost discipline is evident as combined R&D and SG&A expenses fell 23% year‑over‑year, and GAAP SG&A dropped 40% sequentially, reinforcing a lean operating model that supports a cash runway extending well beyond 2028.

The core of Novavax’s growth lies in its Matrix‑M adjuvant platform, now embedded in over 30 unique fields across infectious disease and oncology. Recent material transfer agreements with a top‑10 pharmaceutical firm and multiple new MTAs broaden the addressable market, giving partners rights to explore more than half of the projected $100 billion vaccine and immunotherapeutic opportunity. High‑profile collaborations with Sanofi and Pfizer deliver immediate cash through upfront payments and set the stage for multi‑billion‑dollar milestone and royalty streams, with the Pfizer deal alone offering potential royalties exceeding $1 billion per asset over two decades.

Looking ahead, Novavax is advancing a C. diff vaccine candidate toward clinical trials and leveraging Matrix‑M in oncology pipelines, targeting high‑unmet‑need cancers such as colorectal and pancreatic. The company’s capital‑efficient approach—leveraging partner funding while minimizing internal commercial costs—positions it to capture significant upside as partners transition MTAs into licensed products. With a solid cash base, disciplined expense trajectory, and an expanding partnership ecosystem, Novavax is well‑placed to translate its technology platform into sustained, diversified revenue growth.